Tillkännagivande • 19h
Bio-Works Technologies AB (publ) to Report Q2, 2026 Results on Aug 21, 2026 Bio-Works Technologies AB (publ) announced that they will report Q2, 2026 results on Aug 21, 2026 New Risk • Jul 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (€29.1m market cap, or US$33.3m). Board Change • Jun 07
Less than half of directors are independent Following Director Andrea Ballagi's arrival on 01 June 2026, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Board Director Peter Nahlstedt was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Jun 04
Bio-Works Technologies AB Approves Board Elections Bio-Works Technologies AB at its Annual General Meeting held on June 4, 2026 approved the election of Ms. Eva Lindskog and Ms. Andrea Ballagi as directors of the company. Tillkännagivande • Apr 14
Bio-Works Technologies AB (publ) to Report Q1, 2026 Results on May 13, 2026 Bio-Works Technologies AB (publ) announced that they will report Q1, 2026 results on May 13, 2026 Tillkännagivande • Jan 22
Bio-Works Technologies AB (publ) to Report Fiscal Year 2025 Results on Feb 20, 2026 Bio-Works Technologies AB (publ) announced that they will report fiscal year 2025 results on Feb 20, 2026 Tillkännagivande • Oct 20
Bio-Works Technologies AB (publ) to Report Q3, 2025 Results on Nov 07, 2025 Bio-Works Technologies AB (publ) announced that they will report Q3, 2025 results on Nov 07, 2025 Tillkännagivande • Aug 21
Bio-Works Launches WorkBeads AffimAb Edge: Strategic Expansion in the Protein A Resin Market Bio-Works Technologies AB announced the launch of WorkBeads affimAb Edge, a new premium resin for the purification of monoclonal antibodies (mAbs). The product is designed to meet the high demands of the rapidly growing biopharmaceutical industry and strengthens Bio-Works' position in the key segment of affinity chromatography. The market for Protein A resins is estimated at USD 1-1.4 billion annually, with continued growth driven by increasing demand for efficient purification solutions for antibody-based drugs. Protein A resins are a critical component in the purification process, removing up to 90% of impurities. WorkBeads affim Ab Edge combines high capacity, stability, and cost-efficiency with full regulatory documentation. The product is positioned as a competitive alternative to current market leaders and addresses the needs of both innovative drug developers and contract manufacturers (CMOs/CDMOs). Internal comparison studies show that WorkBeads affimab Edge outperforms the current leading product in the segment. It is developed and manufactured by Korean company PurioGen Inc., rooted in Bio-Works' long-term partner Amicogen. The partnership is based on a Bio-Works technology license and is executed through an exclusive OEM agreement that ensures control over quality, supply, and brand profile. The launch of WorkBeads AffimAb Edge is part of Bio-Works' growth strategy focused on high-margin products and global expansion. By combining technical excellence with commercial scalability, the company strengthens its reputation in the value chain for modern biopharmaceuticals. Tillkännagivande • Jul 24
Bio-Works Technologies AB (publ) to Report Q2, 2025 Results on Aug 22, 2025 Bio-Works Technologies AB (publ) announced that they will report Q2, 2025 results on Aug 22, 2025 Tillkännagivande • May 15
Kirsti Gjellan Declines Re-Election as Director of Bio-Works Technologies Bio-Works Technologies announced that at its annual general meeting was held on 15 May 2025, Kirsti Gjellan had declined re-election as directors. New Risk • Nov 12
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 100% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 4.9% per year over the past 5 years. Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Market cap is less than US$10m (€6.06m market cap, or US$6.44m). Minor Risk Revenue is less than US$5m (kr38m revenue, or US$3.5m). Reported Earnings • Nov 08
Third quarter 2024 earnings released: kr0.12 loss per share (vs kr0.38 loss in 3Q 2023) Third quarter 2024 results: kr0.12 loss per share (improved from kr0.38 loss in 3Q 2023). Revenue: kr10.4m (down 5.0% from 3Q 2023). Net loss: kr5.29m (loss narrowed 62% from 3Q 2023). New Risk • Aug 05
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr56m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr56m free cash flow). Share price has been highly volatile over the past 3 months (46% average weekly change). Earnings have declined by 3.9% per year over the past 5 years. Market cap is less than US$10m (€7.06m market cap, or US$7.70m). Minor Risks Shareholders have been diluted in the past year (9.9% increase in shares outstanding). Revenue is less than US$5m (kr40m revenue, or US$3.8m). Tillkännagivande • May 25
Bio-Works Technologies AB (publ) Approves Appointment of Jonas Ahlen and Thomas Gür as New Board Members Bio-Works Technologies AB (publ) at its AGM held on May 24, 2024 approved appointment of Jonas Ahlen and Thomas Gür as new board members. Tillkännagivande • May 19
Bio-Works Technologies AB (Publ) Announces Executive Changes Bio-Works Technologies AB (publ) announced that effective May 17, 2024, Lone Carlbom has assumed the role of CEO of the company. Concurrently, the company's CEO to date, Jonathan Royce, has resigned from his position in consultation with Bio-Works’ Board of Directors, effective immediately. In line with the CEO transition, Bio-Works’ management team is intended to be reorganized with the following positions: Arne Hauge, CFO and Head of Support Functions, Maria Åberg, Head of Production, Silvia Hellström, Head of Quality Assurance, Lone Carlbom will continue to oversee Product Management and R & D, A new Head of Sales will join the management team shortly. Lone Carlbom brings over 25 years of experience in leadership roles within the Life Sciences and Biotech industries, with expertise in product management, technical support, and sales. Previously, she held the position of Head of Chromatography Resines and BioProcess Equipment at GE Healthcare Life Sciences (now Cytiva). Additionally, she has served as a consultant in change management and organizational development. Tillkännagivande • Apr 26
Bio-Works Technologies AB (publ) Announces Johan Sedihn Declines Re-Election as Member of Board Bio-Works Technologies AB (publ) announced that Johan Sedihn has since informed that he has declined re-election as member of board at the Annual General Meeting. Tillkännagivande • Feb 21
Bio-Works Technologies AB (publ) to Report First Half, 2024 Results on Aug 23, 2024 Bio-Works Technologies AB (publ) announced that they will report first half, 2024 results on Aug 23, 2024 Tillkännagivande • Feb 20
Bio-Works Technologies AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025 Bio-Works Technologies AB (publ) announced that they will report fiscal year 2024 results on Feb 21, 2025 Reported Earnings • Feb 20
Full year 2023 earnings released: kr1.56 loss per share (vs kr1.28 loss in FY 2022) Full year 2023 results: kr1.56 loss per share (further deteriorated from kr1.28 loss in FY 2022). Revenue: kr45.3m (up 9.7% from FY 2022). Net loss: kr53.8m (loss widened 20% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Feb 16
Bio-Works Expands Product Range with Introduction of WorkBeads 40 Butyl SH Bio-Works announced the addition of WorkBeads 40 Butyl SH to its product portfolio. This revolutionary hydrophobic interaction chromatography (HIC) resin is designed for research and industrial-scale purification of proteins, peptides, plasmids, and oligonucleotides. This launch marks a significant expansion of Bio-Works' product range. Advantages of WorkBeads 40 Butyl SH include: High Throughput and Purity: WorkBeads 40 Buty SH offers high binding capacity and purity, enhancing the efficiency of the purification process. Chemical Stability: The resin's high chemical stability allows for easy cleaning-in-place, ensuring reproducible and reliable results. Convenience and Reproducibility: The prepacked GoBio columns provide convenience and reproducibility in purification workflows, saving valuable time and resources. New Risk • Dec 28
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 1.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (kr45m revenue, or US$4.6m). Market cap is less than US$100m (€25.4m market cap, or US$28.2m). Tillkännagivande • Nov 11
Bio-Works Technologies AB (publ), Annual General Meeting, May 24, 2024 Bio-Works Technologies AB (publ), Annual General Meeting, May 24, 2024. Location: Uppsala, Uppsala, Sweden Uppsala Sweden Tillkännagivande • Nov 10
Bio-Works Technologies AB's Nomination Committee for the 2024 Annual General Meeting Bio-Works Technologies AB's Nomination Committee shall consist of representatives of the three shareholders in the company in terms of voting rights who wish to be included in the Nomination Committee according to information from Euroclear Sweden AB as of the last banking day in September. The Nomination Committee has now been constituted and consists of the following members: Staffan Persson, Swedia Invest AB (Chairman of the Nomination Committee), Erik Åfors, Calyptra AB, Dariush Hosseinian, Karkas Captial AB. Recent Insider Transactions • Oct 12
Independent Chairman of the Board recently bought €79k worth of stock On the 10th of October, Peter Ehrenheim bought around 121k shares on-market at roughly €0.65 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Peter has been a buyer over the last 12 months, purchasing a net total of €133k worth in shares. New Risk • Oct 05
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (kr45m revenue, or US$4.1m). Market cap is less than US$100m (€28.0m market cap, or US$29.5m). Tillkännagivande • Sep 07
Bio-Works Technologies AB (Publ) Announces Appointment of Arne Hauge as Chief Financial Officer Bio-Works announced that Arne Hauge has joined the company as Chief Financial Officer. He is joining as a member of Bio-Works executive team and will report directly to CEO, Jonathan Royce. As CFO at Bio-Works Arne Hauge will be responsible for financial management of the company, including leadership of the company’s planning processes, and he will work together with management team to drive Bio-Works to the next stage of growth. Arne Hauge’s latest position was with Felestad Trading AB, as Interim CFO. Arne is a business driven and strategic CFO, with experience from two start-ups - Halebop in Sweden and Yoigo in Spain. During the last two decades at Telia Company AB, he has held various roles, including Investment Manager, CFO, COO, CCO, Strategy & Business Development and M&A. Arne has a long history of working with international businesses. Prior to Telia Company AB, he worked for the chemical company AGA AB, with Financial and Business Control, within Region Latin America and Region Eastern Europe, including two years working in Caracas, Venezuela. Arne has a combination of skills from the start-up and scale-up world, but also solid experience in the area of change management. Breakeven Date Change • Aug 29
Forecast to breakeven in 2025 The analyst covering Bio-Works Technologies expects the company to break even for the first time. New forecast suggests the company will make a profit of kr23.0m in 2025. Average annual earnings growth of 105% is required to achieve expected profit on schedule. Board Change • Aug 29
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. Independent Director Johan Sedihn was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Jun 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Revenue is less than US$5m (kr41m revenue, or US$3.9m). Market cap is less than US$100m (€41.2m market cap, or US$44.4m). Tillkännagivande • May 31
Bio-Works Implements Restructuring Program Bio-Works Technologies AB has enacted a restructuring program to strengthen the company's position and secure the path to profitable growth in 2024. As part of that work, Bio-Works is re-organizing the company with the aim of creating a more efficient organization. The reorganization will reduce the number of employees in Bio-Works from 52 to 40. Bio-Works' local investments to establish the company in the US is not affected by the change. The new organization is expected to positively affect the company's cost structure by approximately SEK 13 million annually. The changes will be implemented in June 2023 and are expected to take effect from autumn 2023. Reported Earnings • Feb 20
Full year 2022 earnings released: kr1.28 loss per share (vs kr0.41 loss in FY 2021) Full year 2022 results: kr1.28 loss per share (further deteriorated from kr0.41 loss in FY 2021). Revenue: kr42.8m (down 24% from FY 2021). Net loss: kr44.8m (loss widened 246% from FY 2021). Revenue is forecast to grow 46% p.a. on average during the next 2 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Tillkännagivande • Dec 22
Bio-Works Technologies AB (publ) Wins EU Grant for Development of Environmentally-Friendly Purification of Biotherapeutics Bio-Works Technologies AB (publ) awarded EU grant for development of environmentally-friendly purification of biotherapeutics. The demand for more environmentally friendly production of pharmaceuticals is growing, thus driving in turn the demand for alternative solutions to purify biopharmaceuticals. Bio-Works has been awarded a 250,000 SEK grant rom the EU's regional structure fund to develop a production method for chromatography resins which eliminates the use of fossil-fuel based solvents. Purification with the help of chromatography resins is a step in the production of biological drugs which is critical to ensure that that the drug can be administered to patients. A new type of resin, based on fossil-fuel free raw materials, would significantly shrink the final product’s total carbon footprint. There are no completely fossil-fuel free resins on the market. The project is planned to be executed during 2023 and is part of the EU’s green initiative with the aim of reducing the region’s carbon footprint. The new production method is expected to be implemented in 2024/2025. Reported Earnings • Aug 22
First half 2022 earnings released: kr0.66 loss per share (vs kr0.29 profit in 1H 2021) First half 2022 results: kr0.66 loss per share (down from kr0.29 profit in 1H 2021). Revenue: kr18.5m (up 124% from 1H 2021). Net loss: kr23.5m (down 365% from profit in 1H 2021). Over the next year, revenue is forecast to grow 53%, compared to a 7.6% growth forecast for the Medical Equipment industry in Germany. Tillkännagivande • Jul 01
Bio-Works Technologies AB (Publ) Launches GoBio, New Product Line Saves Time in Biotherapeutic Production Bio-Works Technologies AB (publ) has launched GoBio, a product line of prepacked chromatography columns designed to span the entire production cycle from process development to commercial production. Prepacked columns enable the user to skip the time consuming and technically complex operation of manually packing resin in columns. By using turnkey products, packed by specialists, up to 5 days can be saved in a production run, and simultaneously a consistent and high level of quality is ensured. Reported Earnings • Feb 19
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: kr0.41 loss per share (up from kr1.48 loss in FY 2020). Revenue: kr57.5m (up kr50.2m from FY 2020). Net loss: kr12.9m (loss narrowed 71% from FY 2020). Revenue exceeded analyst estimates by 10%. Over the next year, revenue is expected to shrink by 45% compared to a 11% growth forecast for the industry in Germany. Tillkännagivande • Feb 18
Bio-Works Signs Licensing Agreement with Amicogen Inc to Establish Local Manufacturing of Agarose Resins in South Korea The agreement entails a technology transfer from Bio-Works to Amicogen to establish in-country production of chromatography products in South Korea. In August 2019, the Korean government initiated a program to establish domestic production of critical raw materials that are used in the production of biotherapeutics. As a result of Amicogen and Bio-Works' longstanding partnership, Amicogen contacted Bio-Works to begin discussing a collaboration on local production. Those discussions have led to the agreement which was signed and takes effect on February 17, 2021. According to the agreement, Bio-Works will deliver documentation and consultation to Amicogen to establish local production of resins which are equivalent to Bio-Works' existing product portfolio. Amicogen will pay $2.22 million upon signing and $1.95 million after 90 days. The remaining $830,000 will be paid when Amicogen has validated their production. The technology transfer is expected to take up to 12 months. Amicogen will gain exclusive rights to the South Korean market and according to the agreement Amicogen will pay Bio-Works a royalty on their net sales until 2031. The Korean market for chromatography resins which are used in biopharmaceutical production is expected to grow to over $94 million by 2025. Bio-Works expects to enter into further discussions with Amicogen regarding future collaborations. This agreement is related to the press release dated December 3, 2020 in which Bio-Works announced that final negotiations with Amicogen had begun. 
